Comet assay reveals no genotoxicity risk of cationic solid lipid nanoparticles

Journal of Applied Toxicology

Volumn 34, Issue 4, 2014, Pages 395-403

  Doktorovova, Slavomira ^a   Silva, Amélia M ^a,b   Gaivão, Isabel ^c   Souto, Eliana B ^a,d   Teixeira, João P ^e   Martins Lopes, Paula ^a  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^d UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^e NATIONAL INSTITUTE OF HEALTH   (Portugal)

Author keywords

Caco 2; Comet assay; Genotoxicity; HepG2; Solid lipid nanoparticles

Indexed keywords

BUFFER; DNA; SOLID LIPID NANOPARTICLE;

ALKALINE COMET ASSAY; ANALYTIC METHOD; ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HEPG2; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DISPERSION; DNA DAMAGE; DRUG FORMULATION; ELECTRICAL POTENTIAL PARAMETERS; GENOTOXICITY; GENOTOXICITY RISK; HUMAN; HUMAN CELL; HYDRODYNAMICS; INTERNALIZATION; PARTICLE SIZE; POLIDISPERSITY INDICE; PRIORITY JOURNAL; RESAZURIN ASSAY; RISK ASSESSMENT;

CACO-2; COMET ASSAY; GENOTOXICITY; HEPG2; SOLID LIPID NANOPARTICLES;

CACO-2 CELLS; CATIONS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; DRUG CARRIERS; DRUG STABILITY; HEP G2 CELLS; HUMANS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84893693696     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2961     Document Type: Article

References (44)

1. 2007. Amended Final Report on the Safety Assessment of Glyceryl Dilaurate, Glyceryl Diarachidate, Glyceryl Dibehenate, Glyceryl Dierucate, Glyceryl Dihydroxystearate, Glyceryl Diisopalmitate, Glyceryl Diisostearate, Glyceryl Dilinoleate, Glyceryl Dimyristate, Glyceryl Dioleate, Glyceryl Diricinoleate, Glyceryl Dipalmitate, Glyceryl Dipalmitoleate, Glyceryl Distearate, Glyceryl Palmitate Lactate, Glyceryl Stearate Citrate, Glyceryl Stearate Lactate, and Glyceryl Stearate Succinate. Int. J. Toxicol. 26(1 supp 3): 1-30. DOI:10.1080/10915810701663143
2. 1990. Final Report on the Safety Assessment of Cocoamphoacetate, Cocoamphopropionate, Cocoamphodiacetate, and Cocoamphodipropionate. Int. J. Toxicol. 9 (2): 121-142. DOI:10.3109/10915819009078729
3. 2008. Safety Assessment of Poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, Poloxamer 105 Benzoate, and Poloxamer 182 Dibenzoate as Used in Cosmetics. Int. J. Toxicol. 27(2 Suppl): 93-128. DOI:10.1080/10915810802244595
4. Ahamed M, Karns M, Goodson M, Rowe J, Hussain SM, Schlager JJ, Hong Y. 2008. DNA damage response to different surface chemistry of silver nanoparticles in mammalian cells. Toxicol. Appl. Pharmacol. 233: 404-410. DOI:10.1016/j.taap.2008.09.015
5. Asasutjarit R, Lorenzen S-I, Sirivichayakul S, Ruxrungtham K, Ruktanonchai U, Ritthidej G. 2007. Effect of Solid Lipid Nanoparticles Formulation Compositions on Their Size, Zeta Potential and Potential for In Vitro pHIS-HIV-Hugag Transfection. Pharm. Res. 24: 1098-1107. DOI:10.1007/s11095-007-9234-3
6. Azqueta A, Shaposhnikov S, Collins AR. 2009. DNA oxidation: Investigating its key role in environmental mutagenesis with the comet assay. Mut. Res. 674: 101-108. DOI:10.1016/j.mrgentox.2008.10.013
7. Barnes CA, Elsaesser A, Arkusz J, Smok A, Palus J, Lesniak A, Salvati A, Hanrahan JP, Jong WHd, Dziubaltowska E, Stepnik M, Rydzynski K, McKerr G, Lynch I, Dawson KA, Howard CV, Vyvyan C. 2008. Reproducible Comet Assay of Amorphous Silica Nanoparticles Detects No Genotoxicity. Nano Lett. 8(9): 3069-3074. DOI:10.1021/nl801661w
8. Beck-Broichsitter M, Rytting E, Lebhardt T, Wang X, Kissel T. 2010. Preparation of nanoparticles by solvent displacement for drug delivery: A shift in the " ouzo region" upon drug loading. Eur. J. Pharm. Sci. 41: 244-253. DOI: 10.1016/j.ejps.2010.06.007
9. Bondi ML, Azzolina A, Craparo EF, Lampiasi N, Capuano G, Giammona G, Cervello M. 2007. Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery. J. Drug Targ. 15: 295-301. DOI:10.1080/10611860701324698%20
10. Doktorovova S, Shegokar R, Rakovsky E, Gonzalez-Mira E, Lopes CM, Silva AM, Martins-Lopes P, Muller RH, Souto EB. 2011. Cationic solid lipid nanoparticles (cSLN): Structure, stability and DNA binding capacity correlation studies. Int. J. Pharm. 420: 341-349. DOI:10.1016/j.ijpharm.2011.08.042
11. Doyle JJ, Doyle JL. 1987. A rapid DNA isolation procedure for small quantities of fresh leaf tissue. Focus 12: 13-15.
12. Dusinska M, Collins AR. 2008. The comet assay in human biomonitoring: gene-environment interactions. Mutagenesis 23: 191-205. DOI:10.1093/mutage/gen007
13. EMEA. 2011. Guideline on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. EMA/CHMP/ICH/126642/2008.
14. Erni C, Suard C, Freitas S, Dreher D, Merkle HP, Walter E. 2002. Evaluation of cationic solid lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen-presenting cells. Biomaterials 23: 4667-4676. DOI:10.1016/S0142-9612(02)00216-8
15. FDA. 2008. S2(R1) Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use.
16. Freitas C, Muller RH. 1999. Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J. Microencapsul. 16: 59-71. DOI:10.1080/026520499289310
17. Guo W, Lee RJ. 2001. Efficient gene delivery via non-covalent complexes of folic acid and polyethylenimine. J. Control. Release 77: 131-138. DOI:10.1016/S0168-3659(01)00456-4
18. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1996. Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals.
19. Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H, Majumdar S, Agrawal GP. 2010. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J.Control Release 148: 359-367. DOI:10.1016/j.jconrel.2010.09.003
20. Joshi M, Pathak S, Sharma S, Patravale V. 2008. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int. J. Pharm. 364: 119-126. DOI:10.1016/j.ijpharm.2008.07.032
21. Karlsson HL, Gustafsson J, Cronholm P, Muller L. 2009. Size-dependent toxicity of metal oxide particles - A comparison between nano- and micrometer size. Toxicol. Lett. 188: 112-118. DOI:10.1016/j.toxlet.2009.03.014
22. Kim HR, Kim MJ, Lee SY, Oh SM, Chung KH. 2011. Genotoxic effects of silver nanoparticles stimulated by oxidative stress in human normal bronchial epithelial (BEAS-2B) cells. Mut. Res. 726: 129-135.
23. Kuo Y-C, Liang C-T. 2011. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials 32: 3340-3350. DOI:10.1016/j.biomaterials.2011.01.048
24. Larson EM, Doughman DJ, Gregerson DS, Obritsch WF. 1997. A new, simple, nonradioactive, nontoxic in vitro assay to monitor corneal endothelial cell viability. Invest. Ophthalmol. Vis. Sci. 38: 1929-1933.
25. Lewinski N, Colvin V, Drezek R. 2008. Cytotoxicity of nanoparticles. Small 4: 26-49. DOI:10.1002/smll.200700595
26. Li X, Nie S-f, Kong J, Li N, Ju C-Y, Pan W-S. 2008. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int. J. Pharm. 363: 177-182. DOI:10.1016/j.ijpharm.2008.07.017
27. Magdolenova Z, Bilanicova D, Pojana G, Fjellsbo LM, Hudecova A, Hasplova K, Marcomini A, Dusinska M. 2012. Impact of agglomeration and different dispersions of titanium dioxide nanoparticles on the human related in vitro cytotoxicity and genotoxicity. J. Environ. Monitor. 14: 455-464. DOI:10.1039/C2EM10746E
28. Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. 2012. Solid lipid nanoparticles as intracellular drug transporters: An investigation of the uptake mechanism and pathway. Int. J. Pharm. 430: 216-227. DOI:10.1016/j.ijpharm.2012.03.032
29. Merhi M, Dombu CY, Brient Ae, Chang J, Platel A, Le Curieux F, Marzin D, Nesslany F, Betbeder D. 2012. Study of serum interaction with a cationic nanoparticle: Implications for in vitro endocytosis, cytotoxicity and genotoxicity. Int. J. Pharm. 423: 37-44. DOI:10.1016/j.ijpharm.2011.07.014
30. Muller R, Shegokar R, Keck C. 2011. 20years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol. 8: 207-227. DOI:10.2174/157016311796799062
31. Müller RH, Rühl D, Runge SA. 1996. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int. J. Pharm. 144: 115-121. DOI:10.1016/S0378-5173(96)04731-X
32. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W. 1997. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14(4): 458-462. DOI:10.1023/A:1012043315093
33. Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar S. 2008. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial A549 cells. Toxicol. Mech. Methods 18: 369-378. DOI:10.1080/15376510801891286
34. Pereira L, Martins-Lopes P, Batista C, Zanol G, Clímaco P, Brazão J, Eiras-Dias J, Guedes-Pinto H. 2012. Molecular markers for assessing must varietal origin. Food Anal. Methods DOI:10.1007/s12161-012-9369-7
35. Pignatello R, Acquaviva R, Campisi A, Raciti G, Musumeci T, Puglisi G. 2011. Effects of liposomal encapsulation on the antioxidant activity of lipophilic prodrugs of idebenone. J. Liposome Res. 21: 46-54. DOI:10.3109/08982101003735996
36. Reineke J, Pacurari M, Castranova V. 2012. Single-Cell Gel Electrophoresis (Comet) Assay in Nano-genotoxicology. In Nanotoxicity, Reineke J (ed.). Humana Press: New York; 57-67.
37. Rivolta I, Panariti A, Lettiero B, Sesana S, Gasco P, Gasco M, Masserini M, Miserocchi G. 2011. Cellular uptake of coumarin-6 as a model drug loaded in solid lipid nanoparticles. J. Physiol. Pharmacol. 62: 45-53.
38. Schubert MA, Muller-Goymann CC. 2005. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur. J. Pharm. Biopharm. 61: 77-86. DOI: 10.1016/j.ejpb.2005.03.006
39. Seyfoddin A, Shaw J, Al-Kassas R. 2010. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 17: 467-489. DOI:10.3109/10717544.2010.483257
40. Shukla R, Sharma V, Pandey A, Singh S, Sultana S, Dhawan A. 2011. ROS-mediated genotoxicity induced by titanium dioxide nanoparticles in human epidermal cells. Toxicol. In Vitro 25: 231-41.
41. Siddiqui A, Patwardhan GA, Liu Y-Y, Nazzal S. 2010. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: In vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells. Int. J. Pharm. 400: 251-259. DOI: 10.1016/j.ijpharm.2010.08.044
42. Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr C-M. 2004. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur. J. Pharm. Biopharm. 57: 155-162. DOI: 10.1016/j.ejpb.2003.10.015
43. Vighi E, Leo E, Montanari M, Mucci A, Hanuskova M, Iannuccelli V. 2011. Structural investigation and intracellular trafficking of a novel multicomposite cationic solid lipid nanoparticle platform as a pDNA carrier. Ther. Deliv. 2: 1419-1435. DOI:10.4155/TDE.11.118
44. Weyenberg W, Filev P, Van den Plas D, Vandervoort J, De Smet K, Sollie P, Ludwig A. 2007. Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int. J. Pharm. 337: 291-298. DOI: 10.1016/j.ijpharm.2006.12.045